Hospital
Lexington Health INC
Lexington Health INC was paid $27.42M by Medicaid between Feb 2021 and Dec 2024, across 408 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 25% of everything it billed.
33Billing provider infoLEXINGTON HEALTH INC
WEST COLUMBIA, SC 29169
WEST COLUMBIA, SC 29169
33aNPI1386241834assigned 10/07/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.42M
24GClaims1,419,978
24DCodes billed408
24AFirst – last monthFeb 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#13 of 115
Median peer was paid$2.47M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BRILLHART, JEFFREY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 393,736 | $7.42M | |
| 2022 | 391,434 | $7.86M | |
| 2023 | 354,795 | $7.20M | |
| 2024incomplete | 280,013 | $4.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 25% | 66,614 | 44,189 | $6.78M |
| J7030 | Infusion, normal saline solution , 1000 cc | 9.0% | 13,526 | 10,038 | $2.48M |
| 80053 | Comprehensive metabolic panel | 6.5% | 59,967 | 51,114 | $1.78M |
| 86900 | 4.5% | 8,110 | 7,220 | $1.22M | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.5% | 22,742 | 20,792 | $962K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.0% | 22,953 | 21,965 | $836K |
| J7050 | Infusion, normal saline solution, 250 cc | 3.0% | 11,178 | 5,690 | $826K |
| 86703 | 2.6% | 11,766 | 11,331 | $700K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 1.6% | 601 | 505 | $426K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 9,810 | 8,659 | $415K |
| 87077 | 1.4% | 15,759 | 14,732 | $394K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 32,131 | 29,142 | $394K |
396 more codes
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1.4% | 3,192 | $387K |
| 99284 | Emergency room visit (serious) | 1.2% | 25,311 | $335K |
| 87081 | 1.2% | 30,631 | $328K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 27,347 | $267K |
| 77062 | <1% | 1,328 | $250K | |
| 81001 | <1% | 29,880 | $249K | |
| 86695 | <1% | 1,430 | $249K | |
| 93971 | <1% | 1,409 | $237K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,133 | $234K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,258 | $220K |
| 80061 | Lipid panel | <1% | 18,610 | $216K |
| 82565 | <1% | 1,218 | $195K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,918 | $179K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,602 | $177K |
| 84439 | <1% | 15,316 | $168K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,040 | $166K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,563 | $165K |
| 82962 | <1% | 6,425 | $162K | |
| 87486 | <1% | 1,504 | $162K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,496 | $160K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,894 | $152K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,121 | $150K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,002 | $137K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,432 | $135K |
| 81025 | <1% | 13,296 | $133K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 11,652 | $116K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,209 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,161 | $113K |
| 84702 | <1% | 8,997 | $105K | |
| 99285 | Emergency room visit (most serious) | <1% | 15,781 | $103K |
| 82950 | <1% | 4,305 | $103K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,274 | $100K |
| 82607 | <1% | 4,121 | $99K | |
| 77336 | <1% | 1,072 | $98K | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 268 | $92K |
| 71250 | <1% | 609 | $85K | |
| 85027 | <1% | 27,900 | $84K | |
| 76642 | <1% | 2,062 | $82K | |
| 87480 | <1% | 1,141 | $82K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 64,162 | $81K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 806 | $77K |
| 87070 | <1% | 2,192 | $76K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 504 | $75K |
| 81511 | <1% | 807 | $73K | |
| 96376 | <1% | 10,465 | $72K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,062 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,364 | $72K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 237 | $69K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,771 | $68K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 189 | $67K |
| G0378 | Hospital observation service, per hour | <1% | 26,638 | $65K |
| 86038 | <1% | 1,873 | $63K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,188 | $61K |
| 73030 | <1% | 1,244 | $61K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,460 | $59K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,603 | $58K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,604 | $57K |
| 82728 | <1% | 4,751 | $54K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,596 | $51K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,342 | $51K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,903 | $50K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,927 | $48K |
| 84112 | <1% | 494 | $48K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,944 | $46K |
| 93970 | <1% | 404 | $42K | |
| 85610 | <1% | 22,807 | $40K | |
| 88304 | <1% | 1,653 | $38K | |
| 73610 | <1% | 461 | $38K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 221 | $37K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,053 | $36K |
| 74018 | <1% | 1,125 | $35K | |
| 82670 | <1% | 426 | $34K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,979 | $33K |
| 87210 | <1% | 1,213 | $32K | |
| 82533 | <1% | 839 | $32K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,282 | $32K |
| 73560 | <1% | 887 | $31K | |
| 77061 | <1% | 251 | $31K | |
| 80076 | <1% | 5,507 | $31K | |
| 83001 | <1% | 1,106 | $29K | |
| 70486 | <1% | 453 | $27K | |
| 72100 | <1% | 1,113 | $26K | |
| 87507 | <1% | 127 | $25K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,604 | $25K |
| 93226 | <1% | 59 | $25K | |
| 78306 | <1% | 64 | $25K | |
| 91300 | <1% | 674 | $24K | |
| 73564 | <1% | 739 | $24K | |
| 73130 | <1% | 442 | $24K | |
| 77334 | <1% | 92 | $24K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 24,048 | $23K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,353 | $23K |
| 73630 | <1% | 666 | $22K | |
| 83735 | <1% | 9,274 | $22K | |
| 83540 | <1% | 5,417 | $22K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,866 | $21K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,675 | $21K |
| 76536 | <1% | 312 | $21K | |
| 82550 | <1% | 2,232 | $21K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,195 | $20K |
| 86140 | <1% | 5,102 | $20K | |
| 84550 | <1% | 1,863 | $20K | |
| 85730 | <1% | 19,005 | $20K | |
| 82570 | <1% | 4,088 | $19K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,085 | $19K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,372 | $19K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,316 | $18K |
| 73090 | <1% | 126 | $18K | |
| 82784 | <1% | 744 | $18K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13,168 | $18K |
| 84146 | <1% | 867 | $18K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,150 | $18K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,529 | $18K |
| 76830 | Ultrasound, transvaginal | <1% | 730 | $17K |
| 83880 | <1% | 10,399 | $16K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 75 | $16K |
| 86704 | <1% | 3,826 | $16K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,130 | $15K |
| 82043 | <1% | 2,070 | $15K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 38 | $14K |
| 97161 | <1% | 2,302 | $14K | |
| 85652 | <1% | 4,434 | $13K | |
| 73502 | <1% | 837 | $13K | |
| 84484 | <1% | 14,274 | $13K | |
| 85378 | <1% | 3,527 | $12K | |
| 82951 | <1% | 1,147 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,001 | $12K |
| 12002 | <1% | 116 | $12K | |
| 73590 | <1% | 294 | $12K | |
| 83690 | <1% | 17,151 | $11K | |
| 87045 | <1% | 152 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,066 | $11K |
| 93225 | <1% | 88 | $11K | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 850 | $11K |
| 49083 | <1% | 44 | $10K | |
| 85018 | <1% | 1,092 | $10K | |
| 95806 | <1% | 104 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,289 | $10K |
| 86850 | <1% | 7,227 | $10K | |
| 93458 | <1% | 259 | $10K | |
| 77300 | <1% | 73 | $10K | |
| 82785 | <1% | 137 | $9K | |
| 88108 | <1% | 92 | $9K | |
| 86235 | <1% | 1,162 | $9K | |
| 88173 | <1% | 441 | $9K | |
| 86780 | <1% | 12,749 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,703 | $9K |
| 76770 | <1% | 212 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 616 | $8K |
| 86706 | <1% | 4,210 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,001 | $8K |
| 88307 | <1% | 930 | $7K | |
| 91307 | <1% | 189 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,072 | $7K |
| 83021 | <1% | 1,054 | $7K | |
| 88184 | <1% | 26 | $7K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,161 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,546 | $6K |
| 77412 | <1% | 85 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 90 | $6K |
| 84144 | <1% | 331 | $6K | |
| 97165 | <1% | 1,337 | $6K | |
| 84403 | <1% | 1,107 | $6K | |
| 86225 | <1% | 1,136 | $6K | |
| 84425 | <1% | 810 | $6K | |
| 84153 | <1% | 509 | $5K | |
| 76801 | <1% | 1,592 | $5K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 539 | $5K |
| 12001 | <1% | 53 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,236 | $5K |
| 83615 | <1% | 904 | $5K | |
| 88142 | <1% | 625 | $5K | |
| 72040 | <1% | 98 | $5K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,408 | $5K |
| 73120 | <1% | 33 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,453 | $5K |
| 86593 | <1% | 51 | $4K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 150 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 44 | $4K |
| 88341 | <1% | 501 | $4K | |
| 86003 | <1% | 162 | $4K | |
| 72141 | <1% | 21 | $4K | |
| 84156 | <1% | 3,139 | $4K | |
| 84155 | <1% | 345 | $4K | |
| 86160 | <1% | 651 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 280 | $4K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,465 | $3K |
| 82746 | <1% | 1,741 | $3K | |
| 82077 | <1% | 3,717 | $3K | |
| 84145 | <1% | 752 | $3K | |
| 86200 | <1% | 510 | $3K | |
| 82947 | <1% | 423 | $3K | |
| 83970 | <1% | 675 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,402 | $3K |
| 87205 | <1% | 2,511 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 452 | $3K |
| 82805 | <1% | 728 | $3K | |
| 87075 | <1% | 1,206 | $3K | |
| 84481 | <1% | 1,391 | $3K | |
| 86803 | <1% | 12,985 | $3K | |
| 84100 | <1% | 1,527 | $3K | |
| 36430 | <1% | 837 | $3K | |
| 73110 | <1% | 27 | $3K | |
| 83520 | <1% | 130 | $3K | |
| 0002A | <1% | 325 | $2K | |
| 82747 | <1% | 1,145 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,808 | $2K |
| 86762 | <1% | 4,510 | $2K | |
| 74220 | <1% | 40 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 559 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,820 | $2K |
| 86709 | <1% | 3,558 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,626 | $2K |
| 85014 | <1% | 1,420 | $2K | |
| 86901 | <1% | 8,107 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,980 | $2K |
| 87632 | <1% | 979 | $2K | |
| 58661 | <1% | 28 | $2K | |
| 91301 | <1% | 54 | $2K | |
| 83013 | <1% | 94 | $2K | |
| 87641 | <1% | 149 | $2K | |
| 87040 | <1% | 2,827 | $2K | |
| 0001A | <1% | 313 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,763 | $2K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 28 | $2K |
| 85045 | <1% | 1,543 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 21,411 | $2K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 15 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 360 | $2K |
| 70496 | <1% | 58 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 907 | $2K |
| 83516 | <1% | 308 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,447 | $2K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 121 | $2K |
| 84270 | <1% | 187 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 93 | $2K |
| 86481 | <1% | 390 | $2K | |
| 81514 | <1% | 2,276 | $2K | |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | <1% | 604 | $2K |
| 74022 | <1% | 37 | $1K | |
| 86787 | <1% | 3,184 | $1K | |
| 82627 | <1% | 14 | $1K | |
| 97116 | <1% | 2,053 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 61 | $1K |
| 87255 | <1% | 25 | $1K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 1,411 | $1K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 774 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,466 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,342 | $1K |
| 73080 | <1% | 14 | $1K | |
| 80164 | <1% | 178 | $1K | |
| 70491 | <1% | 14 | $1K | |
| 74174 | <1% | 48 | $1K | |
| 80069 | <1% | 81 | $1K | |
| 82150 | <1% | 144 | $960.43 | |
| 93017 | <1% | 82 | $866.12 | |
| 82731 | <1% | 13 | $858.99 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,116 | $780.86 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 232 | $776.46 |
| 87640 | <1% | 12 | $750.16 | |
| 81015 | <1% | 587 | $744.09 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,814 | $705.22 |
| 20610 | <1% | 28 | $691.92 | |
| 86147 | <1% | 67 | $685.42 | |
| 82140 | <1% | 355 | $679.77 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 420 | $678.10 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 100 | $670.01 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,990 | $656.66 |
| 0072A | <1% | 117 | $644.40 | |
| 83525 | <1% | 351 | $643.33 | |
| 0071A | <1% | 116 | $608.60 | |
| 85660 | <1% | 972 | $605.16 | |
| 83498 | <1% | 14 | $596.11 | |
| 92526 | <1% | 86 | $589.72 | |
| 87581 | <1% | 1,506 | $547.66 | |
| 86376 | <1% | 353 | $545.63 | |
| 71101 | <1% | 14 | $538.31 | |
| 86769 | <1% | 14 | $527.50 | |
| 72070 | <1% | 29 | $513.57 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,498 | $496.08 |
| 83605 | <1% | 2,565 | $461.57 | |
| 51798 | <1% | 86 | $446.38 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 529 | $414.69 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,664 | $413.18 |
| J1921 | Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg | <1% | 67 | $389.93 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,987 | $379.22 |
| 87340 | <1% | 10,854 | $344.58 | |
| 72170 | <1% | 30 | $317.83 | |
| 88302 | <1% | 99 | $315.32 | |
| 0054A | <1% | 13 | $300.73 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 13 | $291.60 |
| 86039 | <1% | 1,456 | $288.91 | |
| 86777 | <1% | 182 | $279.48 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $271.32 |
| 76870 | <1% | 13 | $252.84 | |
| 75574 | <1% | 15 | $250.41 | |
| 0003A | <1% | 95 | $249.36 | |
| 83550 | <1% | 4,150 | $206.93 | |
| 77066 | Tomosynthesis, mammo | <1% | 1,335 | $203.20 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 50 | $162.39 |
| 86431 | <1% | 1,217 | $137.95 | |
| 90715 | <1% | 757 | $137.24 | |
| 0004A | <1% | 37 | $133.86 | |
| 85613 | <1% | 40 | $114.05 | |
| 0013A | <1% | 21 | $109.01 | |
| 82247 | <1% | 23 | $108.27 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 785 | $104.73 |
| 86696 | <1% | 1,338 | $78.60 | |
| 87186 | <1% | 9,291 | $73.12 | |
| 83921 | <1% | 508 | $71.68 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 564 | $68.48 |
| 87660 | <1% | 1,175 | $62.61 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 17 | $62.02 |
| 83002 | <1% | 294 | $60.01 | |
| 86141 | <1% | 71 | $57.62 | |
| 80177 | <1% | 47 | $55.85 | |
| 84132 | <1% | 209 | $45.02 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 215 | $38.06 |
| 51702 | <1% | 26 | $35.95 | |
| 82575 | <1% | 27 | $35.51 | |
| 70498 | <1% | 60 | $32.39 | |
| 81003 | <1% | 13 | $30.84 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 462 | $18.93 |
| 73552 | <1% | 36 | $16.98 | |
| 86256 | <1% | 115 | $16.31 | |
| 82248 | <1% | 17 | $6.47 | |
| 82952 | <1% | 1,147 | $2.82 | |
| 87899 | 0% | 135 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 178 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 829 | $0.00 |
| C1729 | Catheter, drainage | 0% | 131 | $0.00 |
| 84165 | 0% | 508 | $0.00 | |
| 86923 | 0% | 846 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 441 | $0.00 |
| 87076 | 0% | 12 | $0.00 | |
| 10005 | 0% | 75 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 344 | $0.00 |
| 87106 | 0% | 14 | $0.00 | |
| 99152 | 0% | 376 | $0.00 | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 265 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 225 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 92 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 16 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 265 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 83 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 67 | $0.00 |
| 47563 | 0% | 13 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 237 | $0.00 |
| 77002 | 0% | 13 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 16 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 23 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 57 | $0.00 |
| 76000 | 0% | 13 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 17 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 49 | $0.00 |
| 93312 | 0% | 13 | $0.00 | |
| 73100 | 0% | 12 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 19 | $0.00 |
| 93325 | 0% | 14 | $0.00 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 40 | $0.00 |
| 87185 | 0% | 15 | $0.00 | |
| 86778 | 0% | 182 | $0.00 | |
| 88311 | 0% | 118 | $0.00 | |
| 84480 | 0% | 15 | $0.00 | |
| C1769 | Guide wire | 0% | 2,074 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 355 | $0.00 |
| 86800 | 0% | 124 | $0.00 | |
| 88342 | 0% | 1,273 | $0.00 | |
| 87154 | 0% | 19 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 86920 | 0% | 130 | $0.00 | |
| 84402 | 0% | 113 | $0.00 | |
| 87510 | 0% | 1,139 | $0.00 | |
| 87046 | 0% | 152 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 113 | $0.00 |
| J1335 | Injection, ertapenem sodium, 500 mg | 0% | 55 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 50 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 29 | $0.00 |
| 87181 | 0% | 18 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 48 | $0.00 |
| 90686 | 0% | 26 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 25 | $0.00 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 50 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 13 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 25 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 12 | $0.00 |
| 88185 | 0% | 26 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 31 | $0.00 |
| 19083 | 0% | 27 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 14 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 38 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 39 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 46 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 497 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 18 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRILLHART, JEFFREY (SENIOR VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Lexington Health INC | Lexington, SC | $8.67M |
| Lexington Health INC | Lexington, SC | $5.68M |
| Lexington Health INC | West Columbia, SC | $4.26M |
| Lexington Health INC | Lexington, SC | $4.00M |
| Lexington Health INC | West Columbia, SC | $3.56M |
| Lexington Health INC | Lexington, SC | $2.52M |
| Lexington Health INC | Swansea, SC | $1.26M |
| Lexington Health INC | West Columbia, SC | $1.18M |
| Lexington Health INC | Swansea, SC | $845K |
| Lexington Health INC | West Columbia, SC | $701K |
| Lexington Health INC | Chapin, SC | $631K |
| Lexington Health INC | West Columbia, SC | $598K |
| Lexington Health INC | Batesburg Leesville, SC | $512K |
| Lexington Health INC | West Columbia, SC | $502K |
| Lexington Health INC | West Columbia, SC | $341K |
| Lexington Health INC | West Columbia, SC | $322K |
| Lexington Health INC | West Columbia, SC | $321K |
| Lexington Health INC | West Columbia, SC | $276K |
| Lexington Health INC | West Columbia, SC | $250K |
| Lexington Health INC | Batesburg Leesville, SC | $239K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.